SNMMI: AI enables stress-first SPECT MPI protocol
PHILADELPHIA - Artificial intelligence (AI) analysis of stress SPECT myocardial...Read more on AuntMinnie.comRelated Reading: SNMMI: Early prostate cancer therapy extends lives SNMMI: New therapy aids patients with neuroendocrine tumors SNMMI: AI can predict survival in sarcoma patients SNMMI 2018: A year of promotion and ongoing challenges ASNC releases new guidelines for SPECT MPI
Qi Liu, Dakui Luo, Qingguo Li, Ji Zhu, Xinxiang Li
ConclusionsWhen compared to other radioresistant histologies, HCC has inferior local control and pain relief after SRS. Whether HCC may benefit from further dose escalation or combined treatment with new therapies is an area of future research.
Researchers examined whether a higher Gleason score impacts the efficacy of androgen deprivation therapy.
A recent study inJAMA Oncology compared survival for various multi-modality approaches for treating aggressive prostate cancer.
The long-term results from an analysis of two phase II studies confirmed the role of osimertinib in the treatment of T790M mutation –positive advanced non–small-cell lung cancer.
In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity?
Publication date: Available online 21 September 2018Source: The Lancet HIVAuthor(s): Nancy A Hessol, Hannah Whittemore, Eric Vittinghoff, Ling C Hsu, Danning Ma, Susan Scheer, Sandra K SchwarczSummaryBackgroundCancer survivors are at increased risk for subsequent primary cancers. People living with HIV are at increased risk for AIDS-defining and non-AIDS-defining cancers, but little is known about their risk of first versus second primary cancers. We identified first and second primary cancers that occurred in above population expected numbers among people diagnosed with HIV in San Francisco, and compared first and second ...
PHILADELPHIA - Providing lutetium-177 prostate-specific membrane antigen radioligand...Read more on AuntMinnie.comRelated Reading: Annals: Overdiagnosis must be better defined SNMMI: New therapy aids patients with neuroendocrine tumors SNMMI: AI can predict survival in sarcoma patients SNMMI 2018: A year of promotion and ongoing challenges Faster MRI protocol avoids unneeded prostate biopsies
Conclusion: The cancer burden among PLWH is projected to shift, with prostate and lung cancer expected to emerge as the most common types by 2030. Cancer will remain an important comorbid condition, and expanded access to HIV therapies and cancer prevention, screening, and treatment is needed. Primary Funding Source: National Cancer Institute. PMID: 29801099 [PubMed - as supplied by publisher]
The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLink® Health Plan Claims Database. The expected number of cancer cases in the general population for each gender-age group (60 years) w...